News Quantified

CLDX – celldex therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Celldex to Present at Upcoming Investor Conferences

A Look At Celldex Therapeutics (CLDX) Valuation After Recent Weak Trading Performance [Yahoo! Finance]

MoneyShow's Best Investment Ideas For 2026: Part 3 [Seeking Alpha]

Celldex Therapeutics SVPs Engage In Heavy Transactions [Yahoo! Finance]

Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 [Yahoo! Finance]

7.5%

MISS

-6.1%

MISS

1.3%

BEAT

1.3%

BEAT

Form SCHEDULE 13G Celldex Therapeutics, Filed by: STATE STREET CORP

Form 4 Celldex Therapeutics, For: Jan 02 Filed by: Martin Samuel Bates

Form 4 Celldex Therapeutics, For: Dec 15 Filed by: PEPIN RONALD

Form 4 Celldex Therapeutics, For: Dec 04 Filed by: Jimenez Freddy A.

Form 144 Celldex Therapeutics, Filed by: Jimenez Freddy A.

Top News Gainers

2/20 Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 30.1%

4/28 Form DEF 14A Celldex Therapeutics, For: Jun 18 9.6%

3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus N/A ActVsEst N/A - N/A 3.4%

8/7 Q2/2019 6/30/2019 EPS -0.840 ZacksConsensus -1.170 ActVsEst 0.330 - Beat 2.3%

6/21 Form S-8 Celldex Therapeutics, 2.0%

10/2 Celldex Therapeutics Announces Upcoming Data Presentations 1.9%

10/9 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 1.4%

12/23 Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? [Yahoo! Finance News] 1.3%

2/12 Form SC 13G Celldex Therapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC 0.4%

5/24 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 0.4%

Top News Decliners

3/27 Form 424B5 Celldex Therapeutics, -12.3%

6/1 Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma -9.6%

11/8 CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study -9.2%

12/6 Form S-3 Celldex Therapeutics, -9.1%

11/12 Q3/2019 9/30/2019 EPS -0.750 ZacksConsensus -0.840 ActVsEst 0.090 - Beat -7.3%

11/18 Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 -5.9%

3/3 Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program -4.6%

5/7 Q1/2019 3/31/2019 EPS -1.400 ZacksConsensus -1.140 ActVsEst (0.260) - Miss -3.6%

5/8 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was given a new $19.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -2.8%

7/31 Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call -2.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day